Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ArriVent Biopharma, Inc. (AVBP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$12.23-9.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AVBP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain strong balance sheet to fund operations | ArriVent BioPharma has a stronger balance sheet supporting its pipeline. | Intact | Large dilutive equity raise or debt issuance beyond May 2026 levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is still in a watch state: management has advanced parts of its pipeline, but recent financial performance is weak and confidence in the evidence is low.
The snapshot provides no valuation multiple, peer comparison, or direct measure of market expectations, so whether AVBP is cheap, fair, or expensive cannot be established. No fragility gates fired, but that does not show what clinical progress or future revenue the market already assumes.
Near term, the supplied financials show no revenue and operating losses that widened from $46.111 million in 2026-Q1 to $52.691 million in 2026-Q2. Management has continued pivotal-trial work on firmonertinib, while ARR-217 reached Phase 1b dose optimization and ARR-002 remained on an earlier path toward first-patient dosing; these steps show activity, not proven clinical or commercial delivery. A guidance cut is a stated risk, and overall risk rose recently.
The multi-year thesis hinges on whether firmonertinib and the ADC pipeline produce meaningful clinical progress, and whether ARR-002's licensing agreement eventually shows financial contribution. Near term, weaker jobs data could weigh on healthcare names, while stronger results and guidance from sector bellwethers could support sector momentum. The evidence gives no clinical readout beyond the reported ARR-217 response rate, so broader efficacy conclusions remain uncertain.
Over the next 1 to 3 years, AVBP's case rests on clinical development progress and eventual evidence of commercial or licensing value, while losses, elevated risk, and weak recent performance remain important constraints. The evidence is limited, and the thesis remains in a watch state. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in ArriVent Biopharma, Inc.'s published investment case. The stated target is EPS loss improves to >= -$3.5 in FY27. |
| Under Pressure |
| EPS loss worsens or remains below -$4.0 in FY27 |
Diluted EPS: $-1.05 per share FY2026-Q2; GAAP. Published target: EPS loss improves to >= -$3.5 in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-1.05 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Enrollment progress in ALPACCA Phase 3 study | The company advances enrollment in its ALPACCA Phase 3 study. | Improving | Enrollment progress stalls or falls significantly behind schedule in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve initial revenue from product launches | A primary condition in ArriVent Biopharma, Inc.'s published investment case. The stated target is Revenue >= $42.7M in FY27. | Under Pressure | Revenue falls below $20M in FY27 | Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue >= $42.7M in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.42 → $-3.74 · observed estimates
$0.05B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.42 | $45,781,917 | 7 / 6 |
| 2026-07-25 | $-3.42 | $45,781,917 | 7 / 6 |
| 2026-07-26 | $-3.42 | $45,781,917 | 7 / 6 |
| 2026-07-27 | $-3.42 | $45,781,917 | 7 / 6 |
| 2026-07-28 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-07-29 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-07-30 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-07-31 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-01 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-02 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-03 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-04 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-05 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-06 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-07 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-08 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-09 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-10 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-11 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-12 | $-3.48 | $46,997,660 | 9 / 8 |
| 2026-08-13 | $-3.53 | $48,725,890 | 9 / 7 |
| 2026-08-14 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-15 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-16 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-17 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-18 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-19 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-20 | $-3.42 | $45,781,917 | 6 / 6 |
| 2026-08-21 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-22 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-23 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-24 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-25 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-26 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-27 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-28 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-29 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-30 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-08-31 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-01 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-02 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-03 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-04 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-05 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-06 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-07 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-08 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-09 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-10 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-11 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-12 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-13 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-14 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-15 | $-3.75 | $30,278,182 | 7 / 7 |
| 2026-09-16 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-17 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-18 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-19 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-20 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-21 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-22 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-23 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-24 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-25 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-26 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-27 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-28 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-29 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-09-30 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-01 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-02 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-03 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-04 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-05 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-06 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-07 | $-3.78 | $30,278,182 | 7 / 7 |
| 2026-10-08 | $-3.93 | $9,576,000 | 7 / 6 |
| 2026-10-09 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-10 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-11 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-12 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-13 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-14 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-15 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-16 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-17 | $-3.89 | $7,314,500 | 7 / 7 |
| 2026-10-18 | $-3.86 | $6,740,455 | 7 / 7 |
| 2026-10-19 | $-3.86 | $6,740,455 | 7 / 7 |
| 2026-10-20 | $-3.86 | $6,740,455 | 7 / 7 |
| 2026-10-21 | $-3.86 | $6,740,455 | 7 / 7 |
| 2026-10-22 | $-3.74 | $6,740,455 | 7 / 6 |
| 2026-10-23 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-24 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-25 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-26 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-27 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-28 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-29 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-30 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-10-31 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-11-01 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-11-02 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-11-03 | $-3.74 | $6,740,455 | 7 / 7 |
| 2026-11-04 | $-3.74 | $6,740,455 | 7 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 9 recorded
2 raises · 1 cuts · 0 unchanged · 3 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.